Publications by authors named "Steven Arkin"

Claim this Profile
G
Giroctocogene fitelparvovec gene therapy for severe hemophilia A: 104-week analysis of the phase 1/2 Alta study.
Andrew D Leavitt, Barbara A Konkle, Kimo C Stine, Nathan Visweshwar, Thomas J Harrington, Steven Arkin

Blood· February 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Practical and Statistical Considerations for the Long Term Follow-Up of Gene Therapy Trial Participants.
Maximilian Rohde, Seoan Huh, Vanessa D'Souza, Steven Arkin, Erika Roberts

Clin Pharmacol Ther· January 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Priority Outcomes in Sickle Cell Disease Treatment: Co-Creation and Implementation of a Preference Exercise With Patients and Caregivers to Inform Drug Development.
Maggie Jalowsky, Brett Hauber, Mariah Jacqueline Scott, Steven Arkin, Joshua R Coulter

J Patient Exp· November 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Evolution of Antidrug Antibody Assays During the Development of Anti-Tissue Factor Pathway Inhibitor Monoclonal Antibody Marstacimab.
Jean Donley, Darshana Jani, Tong Zhu, Yuhong Xiang, Boris Gorovits, Steven Arkin

AAPS J· August 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A phase 1b/2 clinical study of marstacimab, targeting human tissue factor pathway inhibitor, in haemophilia.
Johnny N Mahlangu, Jose Luis Lamas, Juan Cristobal Morales, Daniel R Malan, Silva Zupančić Šalek, Steven Arkin

Br J Haematol· January 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
L
Long-term safety and efficacy of the anti-tissue factor pathway inhibitor marstacimab in participants with severe haemophilia: Phase II study results.
Johnny Mahlangu, Jose Luis Lamas, Juan Cristobal Morales, Daniel R Malan, John Teeter, Steven Arkin

Br J Haematol· January 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
V
Validation of patient-reported vaso-occlusive crisis day as an endpoint in sickle cell disease studies.
Karin S Coyne, Brooke M Currie, Michael Callaghan, Kathleen W Wyrwich, Sheryl Pease, Steven Arkin

Eur J Haematol· September 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Phase 1b Study to Evaluate Safety, Tolerability, and Maximum Tolerated Dose of PF-05230907 for Intracerebral Hemorrhage.
Yolanda Silva Blas, Michael N Diringer, Benjamin Lo, Jaime Masjuan, Natalia Pérez de la Ossa, Steven Arkin

Stroke· January 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Evaluation of biomarkers for monitoring thrombogenic potential of FXaI16L.
Michael W Bolt, Fei Hua, Karrie A Brenneman, John E Graves, Steven Arkin

Blood Coagul Fibrinolysis· January 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Domagrozumab (PF-06252616), an Antimyostatin Monoclonal Antibody, in Healthy Subjects.
Indranil Bhattacharya, Sylvester Pawlak, Shannon Marraffino, Jared Christensen, Sarah P Sherlock, Steven Arkin

Clin Pharmacol Drug Dev· June 2018

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
B
Bosutinib versus Placebo for Autosomal Dominant Polycystic Kidney Disease.
Vladimir Tesar, Kazimierz Ciechanowski, York Pei, Irina Barash, Megan Shannon, Steven Arkin

J Am Soc Nephrol· November 2017

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
The quintessence of immunogenicity reporting for biotherapeutics.
Gopi Shankar, Steven Arkin, Viswanath Devanarayan, Arno Kromminga, Valerie Quarmby

Nat Biotechnol· April 2015

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Safety and efficacy of bosutinib (SKI-606) in chronic phase Philadelphia chromosome-positive chronic myeloid leukemia patients with resistance or intolerance to imatinib.
Jorge E Cortes, Hagop M Kantarjian, Tim H Brümmendorf, Dong-Wook Kim, Anna G Turkina, Steven Arkin

Blood· October 2011

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
U
Upregulated ATM gene expression and activated DNA crosslink-induced damage response checkpoint in Fanconi anemia: implications for carcinogenesis.
Kazuhiko Yamamoto, Abdallah Nihrane, Jason Aglipay, Juan Sironi, Steven Arkin

Mol Med· May 2008

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis